ABBVIE INC (ABBV)
US00287Y1091 - Common Stock
Where Will AbbVie Be in 5 Years?
Notable Monday Option Activity: WBA, LBRT, ABBV
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for...
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
The drugmaker has convincingly laid to rest the biggest threat to its top line.
2 Dividend Stocks to Buy Hand Over Fist in November
These companies have solid businesses and excellent dividend growth track records.
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, a first-of-its-kind contest...
Bank of America Takes Over #23 Spot From AbbVie
Why AbbVie Stock Was Getting Mashed on Monday
A splashy recent acquisition by the company might not be panning out.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.
These S&P500 stocks are moving in today's session
Noteworthy Monday Option Activity: TROW, ABBV, MPWR
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.
These S&P500 stocks have an unusual volume in today's session
These S&P500 stocks are moving in today's session
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.
S&P 500 Movers: MPWR, BMY
Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Gap analysis of S&P500 on 2024-11-11: gap up and gap down stocks in today's session.
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails
AbbVie stock also tumbled after its experimental schizophrenia treatment failed in two Phase 2 studies.
AbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials
AbbVie Inc. shares sank in early trading after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment...
3 Spectacular High-Yield Dividend Stocks to Buy in November
High yields aren't a warning indicator with these three stocks.
My Favorite Dividend King to Buy in November
This Dividend King truly wears the crown.
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.